Table 2

Completed Multicenter Trials or Registries of FFRCT

Study Name (Ref. #)NCTnStudy FindingsPer-VesselPer-Patient
Sensitivity,
PPV
Specificity,
NPV
Sensitivity,
PPV
Specificity,
NPV
DISCOVER-FLOW (29)NL103Diagnostic performance trial evaluating first version of FFRCT (version 1.0)88%, 74%82%, 92%93%, 85%81%, 91%
DeFACTO (30)NCT01233518252Diagnostic performance trial evaluating older version of FFRCT (version 1.2)83%, NR78%, NR90%, 67%54%, 84%
NXT (31)NCT01757678254Diagnostic performance trial evaluating latest generation version of FFRCT (version 1.4)84%, 61%86%, 95%86%, 65%79%, 93%
RIPCORD-FFRCT (35)NL200Evaluation of the diagnostic impact of FFRCT to guide medical versus invasive therapies
  • 36% change in management based on FFRCT

  • 23% increase in OMT alone

  • 5% decrease in planned PCI (18% change in target vessel for PCI)

  • 0.5% increase in planned CABG

PLATFORM (41)NCT01943903580Sequential longitudinal cohort study demonstrating 61% reduction in CATH normalcy for FFRCT-guided vs. coronary CTA-guided care

CABG = coronary artery bypass graft; DeFACTO = Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography; DISCOVER-FLOW = Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve; FFRCT = coronary computed tomography angiography–derived fractional flow reserve; NCT = National Clinical Trial; NL = not listed; NPV = negative predictive value; NR = not reported; NXT = Analysis of Coronary Blood Flow Using CT Angiography: Next Steps; OMT = optimal medical therapy; PCI = percutaneous coronary intervention; PLATFORM = Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts; PPV = positive predictive value.